Correlation Between Innate Pharma and HCW Biologics

Can any of the company-specific risk be diversified away by investing in both Innate Pharma and HCW Biologics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Innate Pharma and HCW Biologics into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Innate Pharma and HCW Biologics, you can compare the effects of market volatilities on Innate Pharma and HCW Biologics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Innate Pharma with a short position of HCW Biologics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Innate Pharma and HCW Biologics.

Diversification Opportunities for Innate Pharma and HCW Biologics

0.01

Correlation Coefficient

Innate Pharma  HCW Biologics

Significant diversification

The 3 months correlation between Innate and HCW is 0.01. Overlapping area represents the amount of risk that can be diversified away by holding Innate Pharma and HCW Biologics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on HCW Biologics and Innate Pharma is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Innate Pharma are associated (or correlated) with HCW Biologics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of HCW Biologics has no effect on the direction of Innate Pharma i.e., Innate Pharma and HCW Biologics go up and down completely randomly.

Pair Corralation between Innate Pharma and HCW Biologics

Given the investment horizon of 90 days Innate Pharma is expected to under-perform the HCW Biologics. But the stock apears to be less risky and, when comparing its historical volatility, Innate Pharma is 3.49 times less risky than HCW Biologics. The stock trades about -0.03 of its potential returns per unit of risk. The HCW Biologics is currently generating about 0.02 of returns per unit of risk over similar time horizon. If you would invest  42.00  in HCW Biologics on December 26, 2024 and sell it today you would lose (12.00) from holding HCW Biologics or give up 28.57% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Insignificant
Accuracy	100.0%
Values	Daily Returns

Innate Pharma  vs.  HCW Biologics

Innate Pharma

Risk-Adjusted Performance

Very Weak

Over the last 90 days Innate Pharma has generated negative risk-adjusted returns adding no value to investors with long positions. Despite latest unfluctuating performance, the Stock's technical indicators remain strong and the current disturbance on Wall Street may also be a sign of long term gains for the company investors.

HCW Biologics

Risk-Adjusted Performance

Weak

Compared to the overall equity markets, risk-adjusted returns on investments in HCW Biologics are ranked lower than 1 (%) of all global equities and portfolios over the last 90 days. Despite somewhat weak basic indicators, HCW Biologics sustained solid returns over the last few months and may actually be approaching a breakup point.

Pair Trading with Innate Pharma and HCW Biologics

The main advantage of trading using opposite Innate Pharma and HCW Biologics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Innate Pharma position performs unexpectedly, HCW Biologics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in HCW Biologics will offset losses from the drop in HCW Biologics' long position.

The idea behind Innate Pharma and HCW Biologics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Performance Analysis module to check effects of mean-variance optimization against your current asset allocation.